Aerosol delivery in the treatment of lung cancer

Current Cancer Drug Targets

Volumn 15, Issue 7, 2015, Pages 604-612

  Storti, Chiara ^a   Le Noci, Valentino ^b   Sommariva, Michele ^b   Tagliabue, Elda ^a   Balsari, Andrea ^a,b   Sfondrini, Lucia ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Aerosol delivery; Chemotherapy; Cytokines; Gene therapy; Lung cancer; Monoclonal antibodies; Toll like receptor agonists

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVIDIN; AZACITIDINE; BECLIN 1; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; MACROGOL; OSTEOPONTIN; PACLITAXEL; PROTEIN P53; RUBITECAN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; AEROSOL; ANTINEOPLASTIC AGENT; DRUG CARRIER;

AEROSOL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); GENE THERAPY; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; CHEMISTRY; GENE TRANSFER; GENETICS; INHALATIONAL DRUG ADMINISTRATION; LUNG NEOPLASMS; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84942118597     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150602143751     Document Type: Article

References (81)

1. Armstrong, D.K.; Bundy, B.; Wenzel, L.; Huang, H.Q.; Baergen, R.; Lele, S.; Copeland, L.J.; Walker, J.L.; Burger, R.A. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med., 2006, 354, 34-43.
2. Shalinsky, D.R.; Bischoff, E.D.; Lamph, W.W.; Zhang, L.; Boehm, M.F.; Davies, P.J.A.; Nadzan, A.M.; Heyman, R.A. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res., 1997, 57, 162-168.
3. Guerin, C.; Olivi, A.; Weingart, J.D.; Lawson, H.C.; Brem, H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs, 2004, 22, 27-37.
4. Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res., 1999, 5, 3394-3402.
5. Sharma, S.; White, D.; Imondi, A.R.; Placke, M.E.; Vail, D.M.; Kris, M.G. Development of inhalational agents for oncologic use. J. Clin. Oncol., 2001, 19, 1839-1847.
6. Koshkina, N.V. Kleinerman, E.S. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer, 2005, 116, 458-463.
7. Jia, S.F.; Worth, L.L.; Densmore, C.L.; Xu, B.; Duan, X.; Kleinerman, E.S. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res., 2003, 9, 3462-3468.
8. Khanna, C.; Anderson, P.M.; Hasz, D.E.; Katsanis, E.; Neville, M.; Klausner, J.S. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer, 1997, 79, 1409-1421.
9. Anderson, P.M.; Markovic, S.N.; Sloan, J.A.; Clawson, M.L.; Wylam, M.; Arndt, C.A.; Smithson, W.A.; Burch, P.; Gornet, M.; Rahman, E. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res., 1999, 5, 2316-2323.
10. Maillet, A.; Congy-Jolivet, N.; Le, G.S.; Vecellio, L.; Hamard, S.; Courty, Y.; Courtois, A.; Gauthier, F.; Diot, P.; Thibault, G.; Lemarie, E.; Heuze-Vourc'h, N. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm. Res., 2008, 25, 1318-1326.
11. Maillet, A.; Guilleminault, L.; Lemarie, E.; Lerondel, S.; Azzopardi, N.; Montharu, J.; Congy-Jolivet, N.; Reverdiau, P.; Legrain, B.; Parent, C.; Douvin, D.H.; Hureaux, J.; Courty, Y.; De, M.M.; Diot, P.; Paintaud, G.; Le, P.A.; Watier, H.; Heuze-Vourc'h, N. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm. Res., 2011, 28, 2147-2156.
12. De Santis, R.; Rosi, A.; Anastasi, A.M.; Chiapparino, C.; Albertoni, C.; Leoni, B.; Pelliccia, A.; Santapaola, D.; Carollo, V.; Marra, E.; Aurisicchio, L.; Arseni, B.; Pacello, M.L.; Palmieri, G.; Battella, S.; Petronzelli, F.; Milazzo, F.M. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget, 2014, 5, 9239-9255.
13. Zou, Y.; Tornos, C.; Qiu, X.; Lia, M.; Perez-Soler, R. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin. Cancer Res., 2007, 13, 4900-4908.
14. Lee, H.Y.; Suh, Y.A.; Lee, J.I.; Hassan, K.A.; Mao, L.; Force, T.; Gilbert, B.E.; Jacks, T.; Kurie, J.M. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin. Cancer Res., 2002, 8, 2970-2975.
15. Kim, H.W.; Park, I.K.; Cho, C.S.; Lee, K.H.; Beck, G.R., Jr.; Colburn, N.H.; Cho, M.H. Aerosol delivery of glucosylated polyethylenimine/phosphatase and tensin homologue deleted on chromosome 10 complex suppresses Akt downstream pathways in the lung of K-ras null mice. Cancer Res., 2004, 64, 7971-7976.
16. Xu, C.X.; Jere, D.; Jin, H.; Chang, S.H.; Chung, Y.S.; Shin, J.Y.; Kim, J.E.; Park, S.J.; Lee, Y.H.; Chae, C.H.; Lee, K.H.; Beck, G.R., Jr.; Cho, C.S.; Cho, M.H. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am. J Respir. Crit Care Med., 2008, 178, 60-73.
17. Zamora-Avila, D.E.; Zapata-Benavides, P.; Franco-Molina, M.A.; Saavedra-Alonso, S.; Trejo-Avila, L.M.; Resendez-Perez, D.; Mendez-Vazquez, J.L.; Isaias-Badillo, J.; Rodriguez-Padilla, C. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther., 2009, 16, 892-899.
18. Yu, K.N.; Minai-Tehrani, A.; Chang, S.H.; Hwang, S.K.; Hong, S.H.; Kim, J.E.; Shin, J.Y.; Park, S.J.; Kim, J.H.; Kwon, J.T.; Jiang, H.L.; Kang, B.; Kim, D.; Chae, C.H.; Lee, K.H.; Yoon, T.J.; Beck, G.R.; Cho, M.H. Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS. ONE, 2010, 5, 15623.
19. Garbuzenko, O.B.; Saad, M.; Pozharov, V.P.; Reuhl, K.R.; Mainelis, G.; Minko, T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl Acad. Sci USA., 2010, 107, 10737-10742.
20. Hershey, A.E.; Kurzman, I.D.; Forrest, L.J.; Bohling, C.A.; Stonerook, M.; Placke, M.E.; Imondi, A.R.; Vail, D.M. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res., 1999, 5, 2653-2659.
21. Koshkina, N.V.; Waldrep, J.C.; Roberts, L.E.; Golunski, E.; Melton, S.; Knight, V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res., 2001, 7, 3258-3262.
22. Rodriguez, C.O., Jr.; Crabbs, T.A.; Wilson, D.W.; Cannan, V.A.; Skorupski, K.A.; Gordon, N.; Koshkina, N.; Kleinerman, E.; Anderson, P.M. Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J. Aerosol Med., Pulm. Drug Deliv., 2010, 23, 197-206.
23. Gagnadoux, F.; Leblond, V.; Vecellio, L.; Hureaux, J.; Le, P.A.; Boisdron-Celle, M.; Montharu, J.; Majoral, C.; Fournier, J.; Urban, T.; Diot, P.; Racineux, J.L.; Lemarie, E. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother. Pharmacol., 2006, 58, 237-244.
24. Gagnadoux, F.; Le, P.A.; Urban, T.; Montharu, J.; Vecellio, L.; Dubus, J.C.; Leblond, V.; Diot, P.; Grimbert, D.; Racineux, J.L.; Lemarie, E. Safety of pulmonary administration of gemcitabine in rats. J. Aerosol Med., 2005, 18, 198-206.
25. Gagnadoux, F.; Pape, A.L.; Lemarie, E.; Lerondel, S.; Valo, I.; Leblond, V.; Racineux, J.L.; Urban, T. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur. Respir. J., 2005, 26, 657-661.
26. Min, R.; Li, T.; Du, J.; Zhang, Y.; Guo, J.; Lu, W.L. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can. J. Physiol. Pharmacol., 2008, 86, 288-298.
27. Koshkina, N.V.; Kleinerman, E.S.; Waidrep, C.; Jia, S.F.; Worth, L.L.; Gilbert, B.E.; Knight, V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res., 2000, 6, 2876-2880.
28. Reed, M.D.; Tellez, C.S.; Grimes, M.J.; Picchi, M.A.; Tessema, M.; Cheng, Y.S.; March, T.H.; Kuehl, P.J.; Belinsky, S.A. Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Br. J. Cancer., 2013, 109, 1775-1781.
29. Patel, A.R.; Chougule, M.B.; Patlolla, R.; Wang, G.; Singh, M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm. Res., 2013, 30, 1435-1446.
30. Tatsumura, T.; Koyama, S.; Tsujimoto, M.; Kitagawa, M.; Kagamimori, S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br. J. Cancer, 1993, 68, 1146-1149.
31. Verschraegen, C.F.; Gilbert, B.E.; Loyer, E.; Huaringa, A.; Walsh, G.; Newman, R.A.; Knight, V. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin. Cancer Res., 2004, 10, 2319-2326.
32. Otterson, G.A.; Villalona-Calero, M.A.; Sharma, S.; Kris, M.G.; Imondi, A.; Gerber, M.; White, D.A.; Ratain, M.J.; Schiller, J.H.; Sandler, A.; Kraut, M.; Mani, S.; Murren, J.R. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin. Cancer Res., 2007, 13, 1246-1252.
33. Wittgen, B.P.; Kunst, P.W.; van der, B.K.; van Wijk, A.W.; Perkins, W.; Pilkiewicz, F.G.; Perez-Soler, R.; Nicholson, S.; Peters, G.J.; Postmus, P.E. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res., 2007, 13, 2414-2421.
34. Knight, V.; Koshkina, N.V.; Waldrep, J.C.; Giovanella, B.C.; Gilbert, B.E. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol., 1999, 44, 177-186.
35. Gagnadoux, F.; Vecellio, L.; Prunier, C.; Hureaux, J.; Majoral, C.; Diot, P.; Boisdron, M.; Beaulieu, J.L.; Valat, C.; Halmi, J.M.; Giraudeau, B.; Le Pape, A.; Racineux, J.L.; Urban, T.; Lemarie, E. A phase I study of aerosolized gemcitabine in non-small-cell-lung cancer. J. Aerosol. Med., 2007, 20, 176.
36. Disis, M.L. Mechanism of action of immunotherapy. Semin. Oncol. 2014, 41 Suppl 5:S3-13. doi: 10.1053/j.seminoncol.2014.09.004. Epub;%2014 Sep 6., S3-13.
37. Vacchelli, E.; Eggermont, A.; Sautes-Fridman, C.; Galon, J.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial Watch: Toll-like receptor agonists for cancer therapy. OncoImmunology 2013, 2, e25238.
38. Grimm, E.A. Owen-Schaub, L. The IL-2 mediated amplification of cellular cytotoxicity. J. Cell. Biochem., 1991, 45, 335-339.
39. Zhang, C.; Zhang, J.; Niu, J.; Zhou, Z.; Zhang, J.; Tian, Z. Interleukin-12 improves cytotoxicity of natural killer cells vi upregulated expression of NKG2D. Hum. Immunol., 2008, 69, 490-500.
40. Armitage, J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood, 1998, 92, 4491-4508.
41. Huland, E.; Huland, H.; Heinzer, H. Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J. Urol., 1992, 147, 344-348.
42. Huland, E.; Heinzer, H.; Huland, H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J. Cancer Res., Clin, Oncol., 1994, 120, 221-228.
43. Lorenz, J.; Wilhelm, K.; Kessler, M.; Peschel, C.; Schwulera, U.; Lissner, R.; Struff, W.G.; Huland, E.; Huber, C.; Aulitzky, W.E. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin. Cancer Res., 1996, 2, 1115-1122.
44. Heinzer, H.; Mir, T.S.; Huland, E.; Huland, H. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J. Clin. Oncol., 1999, 17, 3612-3620.
45. Merimsky, O.; Gez, E.; Weitzen, R.; Nehushtan, H.; Rubinov, R.; Hayat, H.; Peretz, T.; Ben-Shahar, M.; Biran, H.; Katsenelson, R.; Mermershtein, V.; Loven, D.; Karminsky, N.; Neumann, A.; Matcejevsky, D.; Inbar, M. Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. Ann. Oncol., 2004, 15, 610-612.
46. Esteban-Gonzalez, E.; Carballido, J.; Navas, V.; Torregrosa, Z.; Munoz, A.; de Mon, M.A. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs, 2007, 18, 291-296.
47. Guma, S.R.; Lee, D.A.; Yu, L.; Gordon, N.; Hughes, D.; Stewart, J.; Wang, W.L.; Kleinerman, E.S. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr. Blood Cancer, 2014, 61, 618-626.
48. Dranoff, G.; Jaffee, E.; Lazenby, A.; Golumbek, P.; Levitsky, H.; Brose, K.; Jackson, V.; Hamada, H.; Pardoll, D.; Mulligan, R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA., 1993, 90, 3539-3543.
49. Rao, R.D.; Anderson, P.M.; Arndt, C.A.; Wettstein, P.J.; Markovic, S.N. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am. J. Clin. Oncol., 2003, 26, 493-498.
50. Link, B.K.; Ballas, Z.K.; Weisdorf, D.; Wooldridge, J.E.; Bossler, A.D.; Shannon, M.; Rasmussen, W.L.; Krieg, A.M.; Weiner, G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother., 2006, 29, 558-568.
51. Krieg, A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 2008, 27, 161-167.
52. Hofmann, M.A.; Kors, C.; Audring, H.; Walden, P.; Sterry, W.; Trefzer, U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother., 2008, 31, 520-527.
53. Leonard, J.P.; Link, B.K.; Emmanouilides, C.; Gregory, S.A.; Weisdorf, D.; Andrey, J.; Hainsworth, J.; Sparano, J.A.; Tsai, D.E.; Horning, S.; Krieg, A.M.; Weiner, G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res., 2007, 13, 6168-6174.
54. Lou, Y.; Liu, C.; Lizee, G.; Peng, W.; Xu, C.; Ye, Y.; Rabinovich, B.A.; Hailemichael, Y.; Gelbard, A.; Zhou, D.; Overwijk, W.W.; Hwu, P. Antitumor activity mediated by CpG: the route of administration is critical. J. Immunother., 2011, 34, 279-288.
55. Nierkens, S.; den Brok, M.H.; Roelofsen, T.; Wagenaars, J.A.; Figdor, C.G.; Ruers, T.J.; Adema, G.J. Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS ONE, 2009, 4, 8368.
56. De Cesare, M.; Calcaterra, C.; Pratesi, G.; Gatti, L.; Zunino, F.; Ménard, S.; Balsari, A. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin. Cancer Res., 2008, 14, 5512-5518.
57. Sfondrini, L.; Sommariva, M.; Tortoreto, M.; Meini, A.; Piconese, S.; Calvaruso, M.; Van, R.N.; Bonecchi, R.; Zaffaroni, N.; Colombo, M.P.; Tagliabue, E.; Balsari, A. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int. J. Cancer, 2013, 133, 383-393
58. Hirota, K.; Oishi, Y.; Taniguchi, H.; Sawachi, K.; Inagawa, H.; Kohchi, C.; Soma, G.; Terada, H. Antitumor effect of inhalatory lipopolysaccharide and synergetic effect in combination with cyclophosphamide. Anticancer Res., 2010, 30, 3129-3134.
59. Zarogoulidis, P.; Darwiche, K.; Hohenforst-Schmidt, W.; Huang, H.; Li, Q.; Freitag, L.; Zarogoulidis, K. Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer. Future Oncol., 2013, 9, 1171-1194.
60. Gautam, A.; Densmore, C.L.; Waldrep, J.C. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene. Ther., 2001, 8, 254-257.
61. Gautam, A.; Densmore, C.L.; Waldrep, J.C. Inhibition of experimental lung metastasis by aerosol delivery of PEI-p53 complexes. Mol Ther., 2000, 2, 318-323.
62. Densmore, C.L.; Kleinerman, E.S.; Gautam, A.; Jia, S.F.; Xu, B.; Worth, L.L.; Waldrep, J.C.; Fung, Y.K.; T'Ang, A.; Knight, V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther., 2001, 8, 619-627.
63. Hasenpusch, G.; Pfeifer, C.; Aneja, M.K.; Wagner, K.; Reinhardt, D.; Gilon, M.; Ohana, P.; Hochberg, A.; Rudolph, C. Aerosolized BC-819 inhibits primary but not secondary lung cancer growth. PLoS ONE, 2011, 6, 20760.
64. Chang, S.H.; Kim, J.E.; Lee, J.H.; Minai-Tehrani, A.; Han, K.; Chae, C.; Cho, Y.H.; Yun, J.H.; Park, K.; Kim, Y.S.; Cho, M.H. Aerosol delivery of eukaryotic translation initiation factor 4Ebinding protein 1 effectively suppresses lung tumorigenesis in KrasLA1 mice. Cancer Gene Ther., 2013, 20, 331-335.
65. Shin, J.Y.; Lim, H.T.; Minai-Tehrani, A.; Noh, M.S.; Kim, J.E.; Kim, J.H.; Jiang, H.L.; Arote, R.; Kim, D.Y.; Chae, C.; Lee, K.H.; Kim, M.S.; Cho, M.H. Aerosol delivery of beclin1 enhanced the anti-tumor effect of radiation in the lungs of K-rasLA1 mice. J. Radiat. Res., 2012, 53, 506-515.
66. Gautam, A.; Waldrep, J.C.; Densmore, C.L.; Koshkina, N.; Melton, S.; Roberts, L.; Gilbert, B.; Knight, V. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther., 2002, 9, 353-357.
67. Hohenforst-Schmidt, W.; Zarogoulidis, P.; Linsmeier, B.; Kioumis, I.; Li, Q.; Huang, H.; Sachpatzidou, D.; Lampaki, S.; Organtzis, J.; Domvri, K.; Sakkas, L.; Zachariadis, G.A.; Archontas, K.N.; Kallianos, A.; Rapti, A.; Yarmus, L.; Zarogoulidis, K.; Brachmann, J. Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System. J. Cancer, 2014, 5, 344-350.
68. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
69. Edwards, D.A. Dunbar, C. Bioengineering of therapeutic aerosols. Annu. Rev. Biomed. Eng., 2002, 4, 93-107.
70. Patton, J.S. Byron, P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov., 2007, 6, 67-74.
71. Koussoroplis, S.J.; Paulissen, G.; Tyteca, D.; Goldansaz, H.; Todoroff, J.; Barilly, C.; Uyttenhove, C.; Van, S.J.; Cataldo, D.; Vanbever, R. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J. Control Release, 2014, 187, 91-100.
72. Meenach, S.A.; Anderson, K.W.; Zach, H.J.; McGarry, R.C.; Mansour, H.M. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci., 2013, 49, 699-711.
73. Swaminathan, J.; Gobbo, O.L.; Tewes, F.; Healy, A.M.; Ehrhardt, C. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin. J. Aerosol. Med. Pulm. Drug Deliv., 2014, 27, 1-11.
74. Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J. Control. Release, 2015, 200, 138-157.
75. Azarmi, S.; Roa, W.H.; Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev., 2008, 60, 863-875.
76. Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D.A.; Edwards, D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. USA., 2002, 99, 12001-12005.
77. Xie, R.L.; Jang, Y.J.; Xing, L.; Zhang, B.F.; Wang, F.Z.; Cui, P.F.; Cho, M.H.; Jiang, H.L. A novel potential biocompatible hyperbranched polyspermine for efficient lung cancer gene therapy. Int. J. Pharm., 2014, 478, 19-30.
78. Taratula, O.; Garbuzenko, O.B.; Chen, A.M.; Minko, T. Innovative strategy for treatment of lung cancer: targeted nanotechnologybased inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target, 2011, 19, 900-914.
79. Conti, D.S.; Brewer, D.; Grashik, J.; Avasarala, S.; da, R., Sr. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol. Pharm., 2014, 11, 1808-1822.
80. Bianchi, A.; Dufort, S.; Lux, F.; Fortin, P.Y.; Tassali, N.; Tillement, O.; Coll, J.L.; Cremillieux, Y. Targeting and in vivo imaging of non-small-cell lung cancer using nebulized multimodal contrast agents. Proc. Natl. Acad. Sci. USA., 2014, 111, 9247-9252.
81. Dufort, S.; Bianchi, A.; Henry, M.; Lux, F.; Le, D.G.; Josserand, V.; Louis, C.; Perriat, P.; Cremillieux, Y.; Tillement, O.; Coll, J.L. Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization. Small, 2015, 11, 215-221.